imported GP that binds to host cell receptors and initiates immune responses. 9 rVSVΔG-ZEBOV-GP provides both pre-and postchallenge protection in animal models. 10, 11 In nonhuman primates, the vaccine was well tolerated 12 and protective against lethal Zaire Ebola virus (ZEBOV) challenges following a single dose. 13 The vaccine induced protective humoral and cellular immune responses in all vaccinated monkeys. 14 As part of a coordinated, international effort to expeditiously evaluate candidate EVD vaccines and make them available to control the epidemic, we conducted a phase 1 trial of the rVSVΔG-ZEBOV-GP. The main objective of this coordinated partnership was to determine the lowest vaccine virus dose that would be safe and well tolerated, and induce an immune response.
Methods

Study design and participants
This was a single-centre, randomized, observer-blind, doseranging, placebo-controlled trial to assess the safety (including rVSV viremia and shedding) and immune response after a single injection of one of 3 dose levels of the rVSVΔG-ZEBOV-GP vaccine. 15 Assessed for eligibility n = 66
Excluded (n = 26)
• Did not meet inclusion criteria (n = 12)
• Declined to participate (n = 6) • Other reasons (n = 8)
Enrolment
Randomized n = 40 Healthy adult male and female volunteers aged 18 to 65 years were randomly assigned in a 1:1:1:1 ratio to one of 3 vaccine groups (1 × 10 5 plaque-forming units [pfu], 5 × 10 5 pfu, and 3 × 10 6 pfu) or a placebo control group (Figure 1) . A randomization list was computer generated with a block size of 8. Exclusions to enrolment included prior infection with a filovirus or VSV or risk of exposure to either; health care worker; child care worker or household contact with young children; pregnant or lactating women; immunocompromised individuals; allergy or any adverse reactions to the vaccine components or other vaccines; underlying medical conditions; and abnormalities on screening tests. Participant screening included medical history, physical examination, electrocardiogram, and blood testing, including complete blood count with white blood cell differential, prothrombin and partial thromboplastin times, serum metabolic panel, urine pregnancy screen (females only), viral serologies (hepatitis B, C, HIV) and urinalysis. The study was conducted at the Canadian Center for Vaccinology in Halifax (clinicaltrials.gov, no. NCT02374385).
Vaccine
The rVSVΔG-ZEBOV-GP vaccine is a live, attenuated recombinant virus in which the GP gene of VSV Indiana strain is replaced by that of the ZEBOV Kikwit 1995 strain. The vaccine was licensed to BioProtection Systems (NewLink Genetics Corporation) and more recently sublicensed to Merck & Co., Inc. Vaccine product was compliant with good manufacturing practices, suspended in recombinant human serum albumin 2.5 g/L and 10 mM Tris (pH 7.2), dispensed at 1 × 10 8 pfu/mL per unit vial and stored at -70ºC (lot number 0030513). Preservativefree normal saline was used as diluent (Alveda NaCl 0.9% lot number: 13331012) to prepare lower doses. Placebo injections were 1 mL normal saline. Study pharmacists prepared allocated treatment; an unblinded nurse concealed and administered it. The pharmacists did not have any interaction with study participants or blinded study staff, and the unblinded nurse had no other role in the study.
Study procedures
Each participant was injected intramuscularly with 1 mL of vaccine or placebo. Participants were monitored at least 30 minutes postinjection for adverse events (AEs). Assessment visits occurred on days 1, 3, 7, 14, 28, 56, 84 and 180. During the 14-day period after injection, solicited and unsolicited AEs were collected using memory aids; subjects recorded temperature, injection-site reactions, serious adverse events (SAEs) or systemic reactogenicity symptoms. Solicited symptoms included injection-site redness, swelling or pain; subjective and objective fever; chills; sweats; myalgia; arthralgia; fatigue; headache; and gastrointestinal symptoms. Thereafter, unsolicited AEs were documented on days 28, 56, 84 and 180. SAEs were monitored throughout the study. The investigator (SAH) assessed all AEs for causality.
The first volunteer was injected only after day 7 data from the first and lowest dose (3 × 10 6 pfu) cohort of a separate doseescalating Walter Reed Army Institute of Research (WRAIR) study 16 were evaluated by the independent Data Safety Monitoring Board. This assured us that we could proceed with our dose-ranging design, as 3 × 10 6 pfu was the highest dose used in this study. Other safety measures included staggered vaccination, follow-up, holding rules and safety monitoring for AEs and SAEs. The study was monitored by an Independent Research Monitor.
Outcomes
The primary outcome was vaccine safety and tolerability through assessment of injection-site events, AEs, SAEs at all visits, and hematologic and biochemical laboratory measures at days 0, 1, 3, 7, 28 and 180, as well as testing for viremia and viral shedding on study days 0-14. Secondary outcomes were antibody measurements on days 0, 7, 14, 28, 56, 84 and 180 by enzyme-linked immunosorbent assay (ELISA), and days 0 and 28 by pseudovirion neutralization assay (PsVNA) 50 and PsVNA80.
An ELISA using recombinant glycoprotein (rGP) from homologous Zaire-Kikwit strain as the solid phase assessed total anti-GP immunoglobulin G (IgG) in sera (Battelle Biomedical Research Center, West Jefferson, OH), Battelle Standard Operating Procedure, BBRC. X-127. [17] [18] [19] A PsVNA measured neutralizing antibody responses to Ebola GP (US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD). 16, [20] [21] [22] [23] [24] This assay is based on non-replicating VSV expressing luciferase reporter protein particles pseudotyped with ZEBOV envelope glycoproteins. 20 The assay determined the highest serum dilutions causing 50% (PsVNA50) and 80% (PsVNA80) inhibition of virus cell entry and expression of luciferase. Note: pfu = plaque-forming units, SD = standard deviation. *Plus-minus values are means ± SD. There were no significant differences between groups. †Race was self-reported.
Real-time reverse-transcriptase polymerase chain reaction (RT-PCR) was performed to identify vaccine rVSV in plasma, saliva or urine through amplification of the VSV-nucleoprotein gene. 16 Routine hematologic, biochemistry and screening serology were performed at the IWK Health Centre using standard methods.
Statistical analysis
Categorical variables were summarized by number and percentage of participants within each category (with a category for missing data) of the parameter. For continuous variables, the number of participants, mean (or geometric mean, where applicable), median, standard deviation (SD) and 95% confidence interval (CI) for the geometric mean, minimum and maximum values were performed. Statistical hypothesis testing of primary and secondary immunogenicity outcomes was conducted at a 2-sided 0.05 significance level; p values were not adjusted for multiplicity. Summary statistics were performed as well as 2-sided 95% CIs on selected parameters. An analysis of variance (ANOVA) regression model was performed to compare log (base 10) transformed ZEBOV IgG concentrations (in ELISA units/mL); pairwise comparisons of antibody concentrations at analysis days 14, 28 and 180 between rVSVΔG-ZEBOV-GP dose levels and between each rVSVΔG-ZEBOV-GP dose level with placebo were performed in the per-protocol population. The ELISA lower limit of quantification was 55.34 units/mL; samples with a concentration at or below the lower limit of quantification were entered as 27.67 for statistical analysis. PsVNA positivity was defined by titers of 20 or higher; values < 20 were assigned 10 for calculation. For both assays, seroconversion was defined as at least 4-fold increase from baseline titer. Antibody titer calculations were on the log 10 scale. Summaries were provided for each vaccine dose and for placebo.
All descriptive statistical analyses were generated using SAS software version 9. 
Ethics approval
Written, informed consent was obtained before any study procedure. The protocol was approved by Health Canada and the Research Ethics Boards of the IWK Health Centre and the Public Health Agency of Canada.
Results
Study participants
A total of 40 participants were vaccinated between Nov. 27 and Dec. 15, 2014 (Table 1) . Mean age was 35.6 years (range 18-62) among vaccine recipients, and 32.0 years (range 20-50) among placebo recipients; 23 were female (57.5%). All participants completed follow-up visits (Figure 1 ).
Safety
There were no SAEs related to the vaccine or withdrawals from the study. The 3 SAE reports from 2 study subjects were cholelithiasis in a recipient of 5 × 10 5 pfu vaccine, and psychotic disorder and major depression in a placebo recipient. All were assessed as being unrelated to the vaccine, and were resolved. Reports of AEs solicited from the participants were primarily characterized as mild to moderate, with 3 separate severe events: headache and diarrhea in the 5 × 10 5 group, and fatigue in the 3 × 10 6 group. Headache was the most frequent systemic reaction overall (Figure 2 ). There were no reports of injection-site swelling or redness; only mild to moderate pain was noted locally. In the first day postvaccination, there was higher incidence of injection-site pain in vaccine recipients compared with placebo. Incidence of injectionsite pain was 0%, 30% and 80% in the 1 × 10 5 pfu, 5 × 10 5 pfu and 3 × 10 6 pfu cohorts, respectively, and 20% in placebo. Arthralgia and myalgia had a similar trend, with frequency on the first day postvaccination higher in vaccine than in placebo recipients. Arthralgia was reported in 10%, 0% and 50% in the 1 × 10 5 pfu, 5 × 10 5 pfu, and 3 × 10 6 pfu dose cohorts, respectively, and 0 in placebo; and the incidence of myalgia was 20%, 0% and 40% in the 1 × 10 5 pfu, 5 × 10 5 pfu and 3 × 10 6 pfu cohorts, respectively, and 10% in placebo. Onset of systemic solicited AEs ranged from as early as the day of injection to 14 days thereafter, lasting 1 to 9 days. Objective fever was not measured in any of the participants. A grade 1 subjective fever (3.3%) was reported by 1 participant who received the 3 × 10 6 pfu dose, and 2 placebo recipients reported grade 1 and grade 2 subjective fever.
Overall, 60% of vaccinees reported unsolicited AEs, yet the incidence of each event was not greater than 2 subjects in any treatment arm (data not shown). Unsolicited AEs were mostly mild to moderate, except a report of severe arthralgia that started at day 18 and lasted 1 day, with no objective signs of arthritis upon immediate examination. No cases of arthritis were observed; however, 1 subject receiving the 3 × 10 6 pfu dose reported grade 1 joint swelling for 14 days, starting at day 13 postvaccination.
Detection of viremia and virus shedding by PCR
Two participants in the 3 × 10 6 pfu group developed viremia by the first day postvaccination, which continued to day 3 for 1 of them. Overall, viremia peaked on study day 3, when 18 (60%) of the 30 vaccinated participants were positive, with the greatest frequency in the highest dose group. All subsequent samples were negative (Table 2 ). There was no virus shedding in saliva or urine. (Table 3) . By day 28, seroconversions had increased to 7 of 10 (70%) who received the 1 × 10 5 pfu or 5 × 10 5 pfu, and all 10 (100%) who received the 3 × 10 6 pfu doses. With the exception of 1 subject in the 1 × 10 5 pfu group, all vaccinees showed seroconversion at some point during the course of the study. Geometric mean titers (GMTs) increased over time from day 0 to day 180, with the exception of a decrease in the 3 × 10 6 pfu dose group from day 28 to day 180. At day 28, there was a nonsignificant trend to higher GMTs in the 3 × 10 6 pfu group compared with the low and medium doses (p = 0.071 and p = 0.054, respectively). Serum IgG titers at study day 180 remained significantly higher in all 3 dose groups compared with placebo. GMT responses were similar in the 1 × 10 5 pfu and 5 × 10 5 pfu dose groups. 
PsVNA titers
Seroconversion by day 28 using PsVNA50 was noted in 8 of 10 (80%) volunteers in the 1 × 10 5 and 5 × 10 5 pfu groups, and in 7 of 10 (70%) of the volunteers in the 3 × 10 6 group (Figure 3) . On day 28, seroconversion by PsVNA80 was less, with rates of 20% (2 of 10 volunteers) in the 1 × 10 5 and 5 × 10 5 pfu groups, and in 1 of 10 (10%) of the volunteers in the 3 × 10 6 group. No difference was observed at baseline between vaccine groups and placebo.
Interpretation
In this phase 1 study, all 3 dose levels of rVSVΔG-ZEBOV-GP live, attenuated vaccine were well tolerated by participants and no safety concerns were identified. Solicited AEs were primarily characterized as mild to moderate, with only 3 severe events (headache and diarrhea in the 5 × 10 5 pfu group; fatigue in the 3 × 10 6 pfu group). Arthralgia during the first 14 days postvaccination was infrequent and not severe. Arthritis was not reported. Viremia was transient, with no detection of vaccine virus shedding in urine or saliva. In the subset of vaccinees who developed viremia, the incidence of frequently reported solicited AEs was similar or moderately increased compared with other vaccinated subjects overall. The vaccine was immunogenic, eliciting glycoprotein-binding antibodies in recipients of all 3 doses. In this report, we provide the first extended postvaccination serology assessments and show that antibody titers persist at high levels 180 days postimmunization.
A phase 1, dose-escalation trial at WRAIR enrolled participants to assess the safety and immunogenicity of 3 × 10 6 pfu and 2 × 10 7 pfu doses. 16 At the United States National Institutes of Health (NIH) Clinical Center, a 2-dose regimen was evaluated using these 2 dose levels. 16 The VSV Ebola Consortium 25 conducted 4 parallel phase 1 trials at sites within Europe and Africa. 24 Three of the 4 trials were open label, uncontrolled and dose escalating, designed to assess the safety, AEs and immunogenicity of rVSVΔG-ZEBOV-GP doses ranging from 3 × 10 5 to 2 × 10 7 pfu. The fourth trial, in Geneva, initially administered the 1 × 10 7 pfu and 5 × 10 7 pfu vaccine doses, but was put on hold as a result of a 25% (13 of 51) and 22% (11 of 51) incidence of fever and oligoarthritis with these 2 doses, respectively. After preliminary data indicated tolerability and immunogenicity of low vaccine doses in other studies, the study was resumed in Geneva, but at a lower dose of 3 × 10 5 pfu, comparing outcomes to those of vaccinees who had received the higher doses before the study was put on hold. 26 Patterns of detectable viremia were comparable with other studies that investigated the rVSVΔG-ZEBOV-GP vaccine; viremia was transient, peaking by day 3 and no longer evident on day 7. 16, 24, 26 Glycoprotein-binding serum antibodies were detectable in all vaccinated individuals, irrespective of vaccine dose. Although neutralizing antibody titers were detected among most participants of our study, a dose response was not evident. A significant dose response for neutralizing antibody titers was not observed in the WRAIR phase 1 trial comparing 3 × 10 6 versus 2 × 10 7 pfu dose, but was observed in the larger VSV Ebola Consortium studies comparing multiple doses between 3 × 10 5 and 5 × 10 7 pfu dose with higher vaccine doses. 16, 24, 26 Unlike higher doses of the rVSVΔG-ZEBOV-GP vaccine, 24 the dose levels tested in our study were minimally reactogenic, which confirms the tolerability of low-dose rVSVΔG-ZEBOV-GP vaccination. 16, 24, 26 There were no reports of arthritis among our cohort for the 180-day followup period, similar to published trials from WRAIR and NIH. 16 Reports of arthritis with overlapping and higher doses of the vaccine suggest an intrinsic association with rVSVΔG-ZEBOV-GP, and not only a dose-dependent one. The multiple phase 1 rVSVΔG-ZEBOV-GP trials across North America (United States and Canada), Europe (Switzerland and Germany) and nonepidemic regions of Africa (Gabon and Kenya) have shown that the vaccine is well tolerated and immunogenic, and warrants further study. The range of doses administered in this study were assessed along with those in the WRAIR and NIH studies and together used to select the optimum dose to be evaluated in the phase 2/3 trials. Currently, there are 4 ongoing phase 2/3 studies: a phase 2 placebo-controlled trial in Liberia, sponsored by the US NIH; a phase 3 ring vaccination trial in Guinea, sponsored by the World Health Organization; a phase 3 trial in Sierra Leone, sponsored by the US Centers for Disease Control and Prevention; and a phase 3 immunogenicity, safety and lot consistency trial in North America and Europe, sponsored by Merck. As part of an African-Canadian collaboration, preparations for a phase 2 trial evaluating the safety and immunogenicity of rVSVΔG-ZEBOV-GP in HIV-infected adults and adolescents are underway with the intent to begin enrolling in 2017.
There are several candidate Ebola vaccines at different stages of development and testing. 27 The rVSVΔG-ZEBOV-GP vaccine is the first to progress to phase 3 trials in Africa after data from the 8 phase 1 studies, including this one, collectively determined that 2 × 10 7 pfu is a favourable dose. Other vaccines include the Ad26-EBOV and MVA-EBOV by Johnson & Johnson and Bavarian Nordic, which have entered phase 2 and 3 trials. The recombinant protein Ebola vaccine by Novavax and Monovalent Ebola Zaire Vaccine (rVSVN4CT1-EBOVGP1) by Profectus BioSciences Inc. are being assessed in phase 1 trials. The replication-defective chimpanzee adenovirus 3 (ChAd3) is completing phase 2 studies.
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Limitations
Limitations of this study are primarily the small sample size, overall and per group, and the fact that only participants from North America were enrolled. Another limitation is the lack of follow-up after six months for long-term immunogenicity data.
Conclusion
Ebola transmission in Africa is now considered to be under control. 2, 31 However, recent clusters of cases are still being reported as a result of virus spread from shedding survivors, and more are anticipated, with the virus still present in sub-Saharan Africa's ecosystem. 32 These facts underscore the importance of continuing efforts and collaborations that may ultimately lead to licensed Ebola vaccines that would protect humans and prevent or control outbreaks in the future. Our study confirms the immunogenicity and tolerability of the rVSVΔG-ZEBOV-GP vaccine, and provides new information about duration of the antibody response.
